Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of JNJ-72537634 (VE202) in Healthy Participants
NCT03931447Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2019
- Primary completion
- Feb 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VE202 in ulcerative colitis (UC) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Treatment Emergent Adverse Events, Serious Adverse Events and 3 more. Started Apr 2019; status: completed.
02
Drugs
VE202
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03931447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931447.